Evidence map›Paper›PMID 26575169›Full record

ArticleOncotarget2015

Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.

Jiao Ma, Wei Xing, Greg Coffey, Karen Dresser, Kellie Lu, Ailin Guo, Gordana Raca, Anjali Pandey, Pamela Conley, Hongbo Yu and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. iScience · 2020
    Article
  15. Review
  16. Role of spleen tyrosine kinase in liver diseases.World journal of gastroenterology · 2020
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Jiao MaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Wei XingDepartment of Pathology, University of Massachusetts Memorial Medical Center and Medical School, Worcester, MA, USA.
Greg CoffeyDepartment of Biology, Portola Pharmaceuticals, Inc., South San Francisco, CA, USA.
Karen DresserDepartment of Pathology, University of Massachusetts Memorial Medical Center and Medical School, Worcester, MA, USA.
Kellie LuUniversity of Chicago Laboratory School, Chicago, IL, USA.
Ailin GuoDepartment of Pathology, Division of Genomic and Molecular Pathology, University of Chicago, Chicago, IL, USA.
Gordana RacaDepartment of Medicine, University of Chicago, IL, USA.
Anjali PandeyDepartment of Biology, Portola Pharmaceuticals, Inc., South San Francisco, CA, USA.
Pamela ConleyDepartment of Biology, Portola Pharmaceuticals, Inc., South San Francisco, CA, USA.
Hongbo YuDepartment of Pathology, University of Massachusetts Memorial Medical Center and Medical School, Worcester, MA, USA.
Y Lynn WangDepartment of Pathology, Division of Genomic and Molecular Pathology, University of Chicago, Chicago, IL, USA.
University of Chicago · USPortola Pharmaceuticals (United States) · USMemorial Medical Center · USCornell University · USUMass Memorial Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B-cell receptor (BCR) and JAK/STAT pathways play critical roles in diffuse large B-cell lymphoma (DLBCL). Herein, we investigated the anti-lymphoma activity of cerdulatinib, a novel compound that dually targets SYK and JAK/STAT pathways. On a tissue microarray of 62 primary DLBCL tumors, 58% expressed either phosphorylated SYK or STAT3 or both. SYK and STAT3 are also phosphorylated in a panel of eleven DLBCL cell lines although ABC and GCB subtypes exhibited different JAK/STAT and BCR signaling profiles. In both ABC and GCB cell lines, cerdulatinib induced apoptosis that was associated with caspase-3 and PARP cleavage. The compound also blocked G1/S transition and caused cell cycle arrest, accompanied by inhibition of RB phosphorylation and down-regulation of cyclin E. Phosphorylation of BCR components and STAT3 was sensitive to cerdulatinib in both ABC and GCB cell lines under stimulated conditions. Importantly, JAK/STAT and BCR signaling can be blocked by cerdulatinib in primary GCB and non-GCB DLBCL tumor cells that were accompanied by cell death. Our work provides mechanistic insights into the actions of cerdulatinib, suggesting that the drug has a broad anti-tumor activity in both ABC and GCB DLBCL, at least in part by inhibiting SYK and JAK pathways.

Indexed as

Antineoplastic AgentsCell Line, TumorCell SurvivalEnzyme InhibitorsFlow CytometryHumansImmunoblottingImmunohistochemistryIntracellular Signaling Peptides and ProteinsJanus KinasesLymphoma, Large B-Cell, DiffuseProtein-Tyrosine KinasesPyrimidinesSignal TransductionSulfonesSyk Kinase4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamideAntineoplastic AgentsEnzyme InhibitorsIntracellular Signaling Peptides and ProteinsJanus KinasesProtein-Tyrosine KinasesPyrimidinesSulfonesSyk KinaseSYK protein, humancerdulatinibdiffuse large B cell lymphomaJAK-STATmolecularly targeted therapySYK

Identifiers

PMID26575169
PMCPMC4791274
OpenAlexW2181172392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.